alzheon, Author at Alzheon | Preserving Future Memories - Page 18 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 208 blog entries.

24 Jul, 2016

Phase 1 Development Of ALZ-801, a Novel Beta Amyloid Anti-aggregation Prodrug of Tramiprosate With Improved Drug Properties, Supporting Bridging to the Phase 3 Program

alzheon2019-09-23T12:10:53-04:00July 24th, 2016|

16 Jun, 2016

Alzheon to Present at the 2016 JMP Securities Life Sciences Conference

alzheon2020-06-26T17:04:08-04:00June 16th, 2016|

11 Mar, 2016

Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate AD: combined sub-group analyses from two Phase 3 trials

alzheon2019-09-23T12:10:53-04:00March 11th, 2016|

11 Mar, 2016

Tramiprosate, an oral amyloid anti-aggregation agent, shows robust cognitive efficacy in APOE4/4 homozygous AD patients: efficacy and safety analyses from two Phase 3 trials

alzheon2019-09-23T12:10:53-04:00March 11th, 2016|

11 Mar, 2016

Alzheon Announces Efficacy Analyses of Prior Tramiprosate Phase 3 Studies Showing Clinically Meaningful Benefits on Key Clinical Endpoints in Alzheimer’s Disease Patients with APOE4 Genotype

alzheon2019-09-23T12:10:53-04:00March 11th, 2016|

11 Mar, 2016

Alzheon Appoints Dennis H. Langer, MD, JD, to Board of Directors

alzheon2020-06-26T17:03:42-04:00March 11th, 2016|

26 Jan, 2016

Alzheon Highlighted as One of the “Top 20 Life Science Startups to Watch in the U.S.”

alzheon2019-09-23T12:10:53-04:00January 26th, 2016|Tags: BioSpace.com|

10 Dec, 2015

Alzheon Appoints Former GlaxoSmithKline CEO Jean-Pierre Garnier as Chairman of Board of Directors

alzheon2020-06-26T17:03:36-04:00December 10th, 2015|

12 Nov, 2015

Alzheon Announces Presentations at Two Upcoming Investor Conferences

alzheon2019-09-23T12:10:53-04:00November 12th, 2015|

6 Nov, 2015

Alzheon Announces Efficacy Outcomes from Two Prior Tramiprosate Phase 3 Studies

alzheon2019-09-23T12:10:53-04:00November 6th, 2015|